Rybelsus Use In Pregnancy & Lactation

Women of childbearing potential: Women of childbearing potential are recommended to use contraception when treated with semaglutide.
Pregnancy: Studies in animals have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). There are limited data from the use of semaglutide in pregnant women. Therefore, semaglutide should not be used during pregnancy. If a patient wishes to become pregnant, or pregnancy occurs, semaglutide should be discontinued.
Semaglutide should be discontinued at least 2 months before a planned pregnancy due to the long half-life (see Pharmacology: Pharmacokinetics under Actions).
Breast-feeding: No measurable concentrations of semaglutide were found in breast milk of lactating women. Salcaprozate sodium was present in breast milk and some of its metabolites were excreted in breast milk at low concentrations. As a risk to a breast-fed child cannot be excluded, Rybelsus should not be used during breast-feeding.
Fertility: The effect of semaglutide on fertility in humans is unknown. Semaglutide did not affect male fertility in rats. In female rats, an increase in oestrous length and a small reduction in number of ovulations were observed at doses associated with maternal body weight loss (see Pharmacology: Toxicology: Preclinical safety data under Actions).